LT3448430T - Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimui - Google Patents

Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimui

Info

Publication number: LT3448430T
Authority: LT; Lithuania
Prior art keywords: idalopirdine; parkinson; disease patients; acetylcholinesterase inhibitor; reducing falls
Prior art date: 2016-04-26

Application number

LTEPPCT/EP2017/059739T

Other languages

English (en)

Inventor

Inge DE JONG

Aaron Kucinski

Martin Sarter

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-26

Filing date

2017-04-25

Publication date

2023-07-25

2017-04-25 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2023-07-25 Publication of LT3448430T publication Critical patent/LT3448430T/lt

Links

YBAWYTYNMZWMMJ-UHFFFAOYSA-N 2-(6-fluoro-1h-indol-3-yl)-n-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine Chemical compound FC(F)C(F)(F)COC1=CC=CC(CNCCC=2C3=CC=C(F)C=C3NC=2)=C1 YBAWYTYNMZWMMJ-UHFFFAOYSA-N 0.000 title 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 title 1
239000000544 cholinesterase inhibitor Substances 0.000 title 1
229950005109 idalopirdine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTEPPCT/EP2017/059739T 2016-04-26 2017-04-25 Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimui LT3448430T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201600248		2016-04-26
PCT/EP2017/059739 WO2017186686A1 (en)	2016-04-26	2017-04-25	Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients

Publications (1)

Publication Number	Publication Date
LT3448430T true LT3448430T (lt)	2023-07-25

Family

ID=58632402

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2017/059739T LT3448430T (lt)	2016-04-26	2017-04-25	Acetilcholinesterazės inhibitoriaus ir idalopirdino panaudojimas, skirtas parkinsono liga sergančių pacientų kritimų skaičiaus sumažinimui

Country Status (28)

Country	Link
US (1)	US10383849B2 (lt)
EP (1)	EP3448430B1 (lt)
JP (1)	JP6992004B2 (lt)
KR (1)	KR102473545B1 (lt)
CN (3)	CN118806909A (lt)
AU (1)	AU2017256623B2 (lt)
BR (1)	BR112017026928B1 (lt)
CA (1)	CA3020557C (lt)
CL (1)	CL2018003013A1 (lt)
CY (1)	CY1126138T1 (lt)
DK (1)	DK3448430T3 (lt)
ES (1)	ES2949288T3 (lt)
FI (1)	FI3448430T3 (lt)
HR (1)	HRP20230693T8 (lt)
HU (1)	HUE062626T2 (lt)
IL (1)	IL262546B (lt)
LT (1)	LT3448430T (lt)
MX (1)	MX387444B (lt)
PL (1)	PL3448430T3 (lt)
PT (1)	PT3448430T (lt)
RS (1)	RS64307B1 (lt)
RU (1)	RU2742173C2 (lt)
SG (1)	SG11201809297UA (lt)
SI (1)	SI3448430T1 (lt)
SM (1)	SMT202300197T1 (lt)
TW (1)	TW201806621A (lt)
WO (1)	WO2017186686A1 (lt)
ZA (1)	ZA201806864B (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX385719B (es) *	2017-05-24	2025-03-18	H Lundbeck As	Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4
WO2019240740A1 (en) *	2017-12-22	2019-12-19	Arasteh Ari Azhir	Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9818914D0 (en) *	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
DE60222396T2 (de) *	2001-03-29	2008-05-15	Eli Lilly And Co., Indianapolis	N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
US20060270709A1 (en) *	2005-04-04	2006-11-30	Eisai Co. Ltd.	Dihydropyridine compounds and compositions for headaches
PE20071143A1 (es) *	2006-01-13	2008-01-20	Wyeth Corp	Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CA2658959A1 (en) *	2006-06-23	2007-12-27	Laboratorios Del Dr. Esteve, S.A.	Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
EP2508177A1 (en) *	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
RU2393158C1 (ru) *	2008-10-06	2010-06-27	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JO3459B1 (ar) *	2012-09-09	2020-07-05	H Lundbeck As	تركيبات صيدلانية لعلاج مرض الزهايمر

2017
- 2017-04-25 CN CN202410836839.2A patent/CN118806909A/zh active Pending
- 2017-04-25 PL PL17719255.6T patent/PL3448430T3/pl unknown
- 2017-04-25 CN CN202410836842.4A patent/CN118806910A/zh active Pending
- 2017-04-25 EP EP17719255.6A patent/EP3448430B1/en active Active
- 2017-04-25 RS RS20230489A patent/RS64307B1/sr unknown
- 2017-04-25 RU RU2018135846A patent/RU2742173C2/ru active
- 2017-04-25 KR KR1020187030934A patent/KR102473545B1/ko active Active
- 2017-04-25 AU AU2017256623A patent/AU2017256623B2/en active Active
- 2017-04-25 SG SG11201809297UA patent/SG11201809297UA/en unknown
- 2017-04-25 FI FIEP17719255.6T patent/FI3448430T3/fi active
- 2017-04-25 DK DK17719255.6T patent/DK3448430T3/da active
- 2017-04-25 SM SM20230197T patent/SMT202300197T1/it unknown
- 2017-04-25 PT PT177192556T patent/PT3448430T/pt unknown
- 2017-04-25 BR BR112017026928-7A patent/BR112017026928B1/pt active IP Right Grant
- 2017-04-25 HU HUE17719255A patent/HUE062626T2/hu unknown
- 2017-04-25 LT LTEPPCT/EP2017/059739T patent/LT3448430T/lt unknown
- 2017-04-25 SI SI201731371T patent/SI3448430T1/sl unknown
- 2017-04-25 US US15/496,159 patent/US10383849B2/en active Active
- 2017-04-25 ES ES17719255T patent/ES2949288T3/es active Active
- 2017-04-25 JP JP2018555748A patent/JP6992004B2/ja active Active
- 2017-04-25 MX MX2018013031A patent/MX387444B/es unknown
- 2017-04-25 HR HRP20230693TT patent/HRP20230693T8/hr unknown
- 2017-04-25 TW TW106113760A patent/TW201806621A/zh unknown
- 2017-04-25 CN CN201780025728.1A patent/CN109069650A/zh active Pending
- 2017-04-25 WO PCT/EP2017/059739 patent/WO2017186686A1/en not_active Ceased
- 2017-04-25 CA CA3020557A patent/CA3020557C/en active Active
2018
- 2018-10-15 ZA ZA2018/06864A patent/ZA201806864B/en unknown
- 2018-10-24 CL CL2018003013A patent/CL2018003013A1/es unknown
- 2018-10-24 IL IL262546A patent/IL262546B/en unknown
2023
- 2023-08-04 CY CY20231100395T patent/CY1126138T1/el unknown

Also Published As

Publication number	Publication date
AU2017256623A1 (en)	2018-11-01
CA3020557A1 (en)	2017-11-02
US10383849B2 (en)	2019-08-20
CL2018003013A1 (es)	2018-12-14
ZA201806864B (en)	2020-01-29
FI3448430T3 (fi)	2023-06-20
EP3448430B1 (en)	2023-06-07
IL262546B (en)	2022-05-01
MX2018013031A (es)	2019-01-17
RU2018135846A3 (lt)	2020-09-30
KR102473545B1 (ko)	2022-12-01
SMT202300197T1 (it)	2023-09-06
ES2949288T3 (es)	2023-09-27
PT3448430T (pt)	2023-07-11
KR20180133869A (ko)	2018-12-17
EP3448430A1 (en)	2019-03-06
BR112017026928B1 (pt)	2023-04-11
CA3020557C (en)	2024-05-21
CN118806910A (zh)	2024-10-22
CN118806909A (zh)	2024-10-22
IL262546A (en)	2018-12-31
PL3448430T3 (pl)	2023-08-21
RS64307B1 (sr)	2023-07-31
JP6992004B2 (ja)	2022-02-03
MX387444B (es)	2025-03-18
TW201806621A (zh)	2018-03-01
HRP20230693T1 (hr)	2023-10-13
CN109069650A (zh)	2018-12-21
AU2017256623B2 (en)	2022-07-21
WO2017186686A1 (en)	2017-11-02
HRP20230693T8 (hr)	2023-11-10
BR112017026928A2 (pt)	2018-08-14
RU2742173C2 (ru)	2021-02-02
US20170304267A1 (en)	2017-10-26
HUE062626T2 (hu)	2023-11-28
RU2018135846A (ru)	2020-05-26
CY1126138T1 (el)	2023-11-15
SI3448430T1 (sl)	2023-08-31
JP2019519480A (ja)	2019-07-11
DK3448430T3 (da)	2023-07-03
SG11201809297UA (en)	2018-11-29

Publication	Publication Date	Title
IL281445A (en)	2021-04-29	Therapeutic nanoparticles and methods for their use
IL252943A0 (en)	2017-08-31	Sunitinib formulations and methods of using them for the treatment of eye diseases
IL246579A0 (en)	2016-08-31	Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease
LT4014976T (lt)	2024-11-11	Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas
PL3676285T3 (pl)	2026-03-23	Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby
IL259862B (en)	2022-04-01	Inhibitors of proton tyrosine kinase and methods of using them
IL274578A (en)	2020-06-30	Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
PT3302454T (pt)	2021-04-01	Composições para utilização no tratamento da doença de parkinson e distúrbios associados
EP3261446A4 (en)	2018-12-05	Methods and compositions for the treatment or prevention of parkinson's disease
IL272495A (en)	2020-03-31	Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA201903828B (en)	2023-02-22	Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
IL265911A (en)	2019-06-30	Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
GB201519557D0 (en)	2015-12-23	Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
ZA201806864B (en)	2020-01-29	Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients
PL3137097T3 (pl)	2023-09-11	Leczenie i profilaktyka choroby Alzheimera (AD)
PT3137094T (pt)	2023-03-09	Tratamento e prevenção da doença de alzheimer (da)
SG11201510451RA (en)	2016-01-28	Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
IL251135A (en)	2017-12-31	A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
PT3137093T (pt)	2017-12-19	Tratamento e prevenção da doença de alzheimer (da)
ZA201801945B (en)	2023-11-29	Compositions and methods for the treatment of parkinson's disease
SG11201701618SA (en)	2017-03-30	Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
GB201718838D0 (en)	2017-12-27	Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en)	2017-09-20	Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201317059D0 (en)	2013-11-06	Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease